Edición de genes para el tratamiento del cáncer de pulmón (CRISPR-Cas9).

IF 0.7 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Colombia Medica Pub Date : 2016-12-29 DOI:10.25100/CM.V47I4.2856

A. Castillo

引用次数: 7

Abstract

In 2015, the journal Science chose CRISPR-Cas9 technology as the most important technological advance of science in the last years1. This magazine announced the beginning of a new era of biotechnology in which it would be possible to edit, correct and modify the genetic information of any cell in a feasible, fast and cheap way; and most importantly, with high precision. Its implementation in research laboratories in basic and applied sciences could help to develop therapeutic strategies for the health area with the main objective of healing diseases with a known genetic origin, and that until now have been impossible to cure.

查看原文本刊更多论文

肺癌治疗的基因编辑(CRISPR-Cas9)。

2015年，《科学》杂志将CRISPR-Cas9技术评为近年来最重要的科学技术进步1。这本杂志宣布了一个生物技术新时代的开始，在这个时代，以一种可行、快速和廉价的方式编辑、纠正和修改任何细胞的遗传信息将成为可能;最重要的是，精度高。在基础科学和应用科学的研究实验室中实施这一方案可以帮助制定保健领域的治疗战略，其主要目标是治疗具有已知遗传起源的疾病，这些疾病迄今无法治愈。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colombia Medica MEDICINE, GENERAL & INTERNAL-

CiteScore

2.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Colombia Médica is an international peer-reviewed medical journal that will consider any original contribution that advances or illuminates medical science or practice, or that educates to the journal''s’ readers.The journal is owned by a non-profit organization, Universidad del Valle, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE) and the World Association of Medical Editors (WAME) recommendations of policies on publication ethics policies for medical journals. Colombia Médica publishes original research articles, viewpoints and reviews in all areas of medical science and clinical practice. However, Colombia Médica gives the highest priority to papers on general and internal medicine, public health and primary health care.